Gene health startup Annroad receives USD 106M for Series C
Founded in: 2012
Financing status: RMB 700 million (USD 106 million) for Series C financing in 2017
Gene health startup, Annroad, received USD 106M for Series C on November 2nd to improve its gene related research.
Annroad is a tech startup known for its dedication in the gene health field, with a focus on developing novel diagnostic products and assisting life science research. Moreover, it offers sequencing and bioinformatic analysis service to meet the demands of life science research. The company aims to build a gene oriented platform to facilitate the discovery of life science, so that humans can lead a better life.
Founded in 2012 in Beijing, Annoroad’s proprietary technologies of bioinformatics and sequencing platforms have entered into a strategic cooperation with Illumina and AliClound in order to shape its competitive Bio-IT background and industrialization capabilities.
Besides, Annoroad has constructed a multinational team of genomic experts, medical specialists to promote the development of human gene health. It is expected to set up a new system for the scope of individualized cancer therapy, monogenic inheritance testing, genetic examination, and reproductive healthcare.
This Series C financing round was led by GTJA Investment Group, which focuses on investment in the medical health industry, and Ping An Ventures, with SoftBank China Capital and SAIF Partners China participating as investors. The company plans to use the funds to recruit more talent to build a rich human source system, invest in the research and development of gene products, as well as expand its services overseas.
（Top photo from 699pic.com）